Results =
Confidence. Clinical Data.

Aubagio quietsMS in three ways.^*

^*AUBAGIO is effective across key measures of disease activity: sustained disability progression^† (14 mg only), annualized relapse rate, and MRI activity. Overall discontinuation rates due to adverse events were 12.5% with AUBAGIO 14 mg, 11.2% with AUBAGIO 7 mg, and 7.5% with placebo, and discontinuation rates due to common adverse events were ≤3.3% in the pooled clinical trials.

^†Doctors measure disability progression using a test called the Expanded Disability Status Scale, or EDSS. Your first score—or your “baseline”—will determine how your disability is gauged moving forward. If your baseline score is ≤5.5, you’re considered to have sustained disability progression if that score goes up by one point (lasting at least 12 weeks). If your baseline score is >5.5, you’re considered to have sustained disability progression if that score goes up by at least 0.5 point (lasting at least 12 weeks).

^‡14 mg only.

Ask your doctor if AUBAGIO is right for you.